Abstract: Throughout development of iPSC-derived immune effector cell therapies, Century recognizes the critical importance of cellular product manufacturing, and is committed to building in-house GMP Operation capabilities and expertise. This investment will not only enable vertical integration of the company, but also bring benefits such as iterative learnings from clinical production, improved probability of success for process and analytical technology transfer, the ability to better troubleshoot problems and optimize processes.